FeesSafety
Pluang+

OXB partners with Aura Biosciences to support Phase 3 and commercial manufacturing of cancer therapy candidate.

Market News
17 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
OXB partners with Aura Biosciences to support Phase 3 and commercial manufacturing of cancer therapy candidate.

OXB has confirmed its partnership with Aura Biosciences to support the Phase 3 development and potential commercial supply of Aura's lead oncology candidate, belzupacap sarotalocan (bel-sar). OXB will provide manufacturing and process development from its FDA-approved facilities in the US, leveraging over 30 years of viral vector expertise. This collaboration aims to ensure robust manufacturing processes for late-stage clinical development and future commercialization of this promising cancer therapy. The partnership also marks OXB's expansion into virus-like drug conjugate manufacturing, enhancing its service offerings in advanced therapies.

OXB's partnership with Aura Biosciences is the subject here, providing context from Pluang's Health sector data. For readers following Health stocks, 50 of 150 priced US stocks rose and 84 fell today. Notable movers include BBIO at USD 79.41 with a 2.65% increase and a typical hold time of 65 days, DYN at USD 17.11 with a 2.46% rise, and EXEL at USD 65.50 down 2.38% with 100% sell order activity. This snapshot is as of Nov 17, 2026 18:01 WIB.

More News

Microsoft expands use of Haivision tech for live production of 600+ global events annually

Microsoft expands use of Haivision tech for live production of 600+ global events annually

Microsoft has expanded its partnership with Haivision by adopting the Makito ONE video transport platform, Makito X4 video encoders and decoders, Haivision Pro mobile transmitters, and Haivision Hub 360 for live production of over 600 global events e...

Market News
Bullish
1 hour ago
Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Piper Sandler upgraded Medtronic to Overweight with a $120 price target, citing strategic growth through acquisitions and product launches in vascular, heart rhythm, and robotic surgery. Medtronic's recent acquisition of Contego Medical expands its c...

Analyst Insights
Bullish
2 hours ago
NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA's Board of Directors has established the National Security and Export Control Oversight Committee to manage the company's national security policies and export control compliance. Chaired by Suzanne Nora Johnson, the committee will oversee NVI...

Market News
Neutral
2 hours ago
Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market is projected to grow from $13.85 billion in 2027 to $25.65 billion by 2032, with a CAGR of 13.12%. Growth is fueled by increased smartphone use, digital wallet adoption, expanding logistics, and social commerce. B2C remai...

Market News
Bullish
2 hours ago
Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock Biotech Limited announced its 2026 Annual General Meeting will be held on December 22, 2026, at its Shanghai office. The meeting will cover ratifying Ernst & Young Hua Ming LLP as auditor for 2026, re-electing directors Zhihong Zhang and...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App